000650 仁和药业
已收盘 07-05 15:00:00
资讯
新帖
简况
仁和药业(000650.SZ)2023年年度权益分派：每10股派2元 7月5日股权登记
智通财经 · 06-27
仁和药业(000650.SZ)2023年年度权益分派：每10股派2元 7月5日股权登记
仁和药业：截止2024年6月20日，大约9.8万户左右
证券之星 · 06-25
仁和药业：截止2024年6月20日，大约9.8万户左右
仁和药业（000650）6月20日主力资金净卖出8615.07万元
证券之星 · 06-21
仁和药业（000650）6月20日主力资金净卖出8615.07万元
仁和药业（000650）6月13日主力资金净卖出1286.96万元
证券之星 · 06-14
仁和药业（000650）6月13日主力资金净卖出1286.96万元
【机构调研记录】鹏华基金调研西大门、仁和药业等4只个股（附名单）
证券之星 · 05-23
【机构调研记录】鹏华基金调研西大门、仁和药业等4只个股（附名单）
【机构调研记录】睿远基金调研裕太微、仁和药业等3只个股（附名单）
证券之星 · 05-23
【机构调研记录】睿远基金调研裕太微、仁和药业等3只个股（附名单）
【机构调研记录】国联安基金调研仁和药业
证券之星 · 05-23
【机构调研记录】国联安基金调研仁和药业
【机构调研记录】农银汇理基金调研仁和药业
证券之星 · 05-23
【机构调研记录】农银汇理基金调研仁和药业
仁和药业最新公告：子公司近日收到磷酸奥司他韦胶囊《药品注册证书》
证券之星 · 05-22
仁和药业最新公告：子公司近日收到磷酸奥司他韦胶囊《药品注册证书》
仁和药业(000650.SZ)：磷酸奥司他韦胶囊收到药品注册证书
智通财经 · 05-22
仁和药业(000650.SZ)：磷酸奥司他韦胶囊收到药品注册证书
仁和药业（000650）5月16日主力资金净卖出8255.32万元
证券之星 · 05-17
仁和药业（000650）5月16日主力资金净卖出8255.32万元
仁和药业：根据相关法规，请您先向公司证券部提交股东身份证明
证券之星 · 05-14
仁和药业：根据相关法规，请您先向公司证券部提交股东身份证明
仁和药业：截止2024年4月30日，大约10万户左右
证券之星 · 05-10
仁和药业：截止2024年4月30日，大约10万户左右
仁和药业（000650）4月29日主力资金净买入2178.22万元
证券之星 · 04-30
仁和药业（000650）4月29日主力资金净买入2178.22万元
图解仁和药业一季报：第一季度单季净利润同比减2.74%
证券之星 · 04-29
图解仁和药业一季报：第一季度单季净利润同比减2.74%
仁和药业最新公告：一季度归母净利润1.77亿元 同比下降2.74%
证券之星 · 04-29
仁和药业最新公告：一季度归母净利润1.77亿元 同比下降2.74%
仁和药业：一季度净利润1.77亿元，同比下降2.74%
澎湃新闻 · 04-29
仁和药业：一季度净利润1.77亿元，同比下降2.74%
仁和药业(000650.SZ)发布一季度业绩，净利润1.77亿元，下降2.74%
智通财经 · 04-29
仁和药业(000650.SZ)发布一季度业绩，净利润1.77亿元，下降2.74%
仁和药业(000650.SZ)发布2023年度业绩，净利润5.67亿元，下降1.25%
智通财经网 · 04-25
仁和药业(000650.SZ)发布2023年度业绩，净利润5.67亿元，下降1.25%
仁和药业最新公告：拟使用合计不超30亿元进行投资理财
证券之星 · 04-25
仁和药业最新公告：拟使用合计不超30亿元进行投资理财
加载更多
公司概况
公司名称：
仁和药业股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-10
主营业务：
仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。
发行价格：
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":6.04,"timestamp":1720163028000,"preClose":5.94,"halted":0,"volume":15759074,"delay":0,"floatShares":1331000000,"shares":1400000000,"eps":0.4017,"marketStatus":"已收盘","marketStatusCode":5,"change":0.1,"latestTime":"07-05 15:00:00","open":5.92,"high":6.06,"low":5.9,"amount":94460400,"amplitude":0.0269,"askPrice":6.05,"askSize":863,"bidPrice":6.04,"bidSize":3782,"shortable":0,"etf":0,"ttmEps":0.4017,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720402200000},"adr":0,"adjPreClose":5.94,"symbolType":"stock","openAndCloseTimeList":[[1720143000000,1720150200000],[1720155600000,1720162800000]],"highLimit":6.53,"lowLimit":5.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"pbRate":1.36,"roa":"--","roe":"2.92%","epsLYR":0.41,"committee":0.121013,"marketValue":8456000000,"floatMarketCap":8042000000,"peRate":15.036097,"changeRate":0.0168,"turnoverRate":0.0118,"status":0},"requestUrl":"/m/hq/s/000650","defaultTab":"news","newsList":[{"id":"2446553157","title":"仁和药业(000650.SZ)2023年年度权益分派：每10股派2元 7月5日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2446553157","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446553157?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:18","pubTimestamp":1719490714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)发布公告，公司2023年年度权益分派方案为：以公司现有总股本剔除已回购股份为基数，向全体股东每10股派2元人民币现金(含税)，股权登记日：2024年7月5日，除权除息日：2024年7月8日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0097","BK0239","000650"],"gpt_icon":0},{"id":"2446818226","title":"仁和药业：截止2024年6月20日，大约9.8万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2446818226","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446818226?lang=zh_cn&edition=full","pubTime":"2024-06-25 18:04","pubTimestamp":1719309878,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业06月25日在投资者关系平台上答复投资者关心的问题。公司销售生产、经营管理等一切正常。公司今年一季度有1.77亿归母利润，二季度也是正常，现金流稳健。公司根据财务的安排，2023年度分红工作计划在7月上旬进行。截止2024年6月20日，大约9.8万户左右。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500034816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0239","BK0188","BK0097"],"gpt_icon":0},{"id":"2445274027","title":"仁和药业（000650）6月20日主力资金净卖出8615.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445274027","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445274027?lang=zh_cn&edition=full","pubTime":"2024-06-21 09:19","pubTimestamp":1718932765,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月20日收盘，仁和药业报收于5.88元，下跌6.07%，换手率4.27%，成交量56.8万手，成交额3.4亿元。近5日资金流向一览见下表：仁和药业融资融券信息显示，融资方面，当日融资买入2415.12万元，融资偿还9262.66万元，融资净偿还6847.54万元。仁和药业主营业务：生产、销售中西药、原料药及健康相关产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100015655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","000650","BK0188"],"gpt_icon":0},{"id":"2443669053","title":"仁和药业（000650）6月13日主力资金净卖出1286.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443669053","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443669053?lang=zh_cn&edition=full","pubTime":"2024-06-14 09:04","pubTimestamp":1718327061,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月13日收盘，仁和药业报收于6.42元，下跌3.02%，换手率2.72%，成交量36.2万手，成交额2.34亿元。近5日资金流向一览见下表：仁和药业融资融券信息显示，融资方面，当日融资买入2551.09万元，融资偿还2066.82万元，融资净买入484.26万元。仁和药业主营业务：生产、销售中西药、原料药及健康相关产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400012613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0188","BK0097"],"gpt_icon":0},{"id":"2437226601","title":"【机构调研记录】鹏华基金调研西大门、仁和药业等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2437226601","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437226601?lang=zh_cn&edition=full","pubTime":"2024-05-23 08:01","pubTimestamp":1716422516,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月22日披露的机构调研信息，鹏华基金近期对4家上市公司进行了调研，相关名单如下：1）西大门 个股亮点：公司2023半年报显示：公司试水海外电商业务，通过在亚马逊等海外线上平台建立销售渠道，拓展海外客户，已实现多维度布局，上半年亚马逊等海外线上平台销售收入同比增加240.85%；公司所生产的功能性遮阳材料主要应用于玻璃窗户、阳光房、玻璃顶篷等内遮阳领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300010455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605155","BK0188","BK0239","000650","BK0247","BK0097"],"gpt_icon":0},{"id":"2437226942","title":"【机构调研记录】睿远基金调研裕太微、仁和药业等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2437226942","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437226942?lang=zh_cn&edition=full","pubTime":"2024-05-23 08:01","pubTimestamp":1716422508,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月22日披露的机构调研信息，睿远基金近期对3家上市公司进行了调研，相关名单如下：1）裕太微 个股亮点：公司自主研发的车载 百兆以太网物理层芯片已通过AEC-Q100Grade1车规认证。睿远基金成立于2018年，截至目前，资产管理规模394.79亿元，排名91/203；资产管理规模394.78亿元，排名77/203；管理公募基金数8只，排名166/203；旗下公募基金经理5人，排名143/203。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300010441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","BK0239","BK0097","000650","688515","BK0188","BK0231"],"gpt_icon":0},{"id":"2437226946","title":"【机构调研记录】国联安基金调研仁和药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2437226946","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437226946?lang=zh_cn&edition=full","pubTime":"2024-05-23 08:01","pubTimestamp":1716422490,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月22日披露的机构调研信息，国联安基金近期对1家上市公司进行了调研，相关名单如下：1）仁和药业 个股亮点：公司涉足互联网电商和医疗推出叮当健康大平台,横跨大健康商品直供、智能设备实时监测、健康大数据管理、远程医疗服务、送药上门等:实控人旗下拥有叮当快药；公司对治疗传染性肝炎、慢性肝炎和乙型肝炎或类似症状等产品共有7个产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300010411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0239","BK0188"],"gpt_icon":0},{"id":"2437226179","title":"【机构调研记录】农银汇理基金调研仁和药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2437226179","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437226179?lang=zh_cn&edition=full","pubTime":"2024-05-23 08:01","pubTimestamp":1716422476,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月22日披露的机构调研信息，农银汇理基金近期对1家上市公司进行了调研，相关名单如下：1）仁和药业 个股亮点：公司涉足互联网电商和医疗推出叮当健康大平台,横跨大健康商品直供、智能设备实时监测、健康大数据管理、远程医疗服务、送药上门等:实控人旗下拥有叮当快药；公司对治疗传染性肝炎、慢性肝炎和乙型肝炎或类似症状等产品共有7个产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300010392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"gpt_icon":0},{"id":"2437253242","title":"仁和药业最新公告：子公司近日收到磷酸奥司他韦胶囊《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2437253242","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437253242?lang=zh_cn&edition=full","pubTime":"2024-05-22 16:23","pubTimestamp":1716366212,"startTime":"0","endTime":"0","summary":"仁和药业公告，子公司江西药都仁和制药有限公司近日收到国家药品监督管理局核准签发的关于磷酸奥司他韦胶囊《药品注册证书》。磷酸奥司他韦是一种流感病毒神经氨酸酶抑制剂(NAI)，适用于（1）用于成人和1岁及以上儿童的甲型和乙型流感治疗。（2）用于成人和13岁及以上青少年的甲型和乙型流感的预防。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200028527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","BK0239","000650"],"gpt_icon":0},{"id":"2437408237","title":"仁和药业(000650.SZ)：磷酸奥司他韦胶囊收到药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437408237","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437408237?lang=zh_cn&edition=full","pubTime":"2024-05-22 15:46","pubTimestamp":1716363965,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)公告，公司子公司江西药都仁和制药有限公司近日收到国家药品监督管理局核准签发的关于磷酸奥司他韦胶囊《药品注册证书》。磷酸奥司他韦是一种流感病毒神经氨酸酶抑制剂(NAI)，适用于：用于成人和1岁及1岁以上儿童的甲型和乙型流感治疗(磷酸奥司他韦能够有效治疗甲型和乙型流感，但是乙型流感的临床应用数据尚不多)。患者应在首次出现症状48小时以内使用。用于成人和13岁及13岁以上青少年的甲型和乙型流感的预防。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0097","BK0239","000650"],"gpt_icon":0},{"id":"2436691937","title":"仁和药业（000650）5月16日主力资金净卖出8255.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436691937","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436691937?lang=zh_cn&edition=full","pubTime":"2024-05-17 09:20","pubTimestamp":1715908850,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月16日收盘，仁和药业报收于7.08元，下跌1.94%，换手率3.5%，成交量46.54万手，成交额3.31亿元。近5日资金流向一览见下表：仁和药业融资融券信息显示，融资方面，当日融资买入2101.22万元，融资偿还4028.83万元，融资净偿还1927.62万元。仁和药业主营业务：生产、销售中西药、原料药及健康相关产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700015501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","BK0239","000650"],"gpt_icon":0},{"id":"2435151191","title":"仁和药业：根据相关法规，请您先向公司证券部提交股东身份证明","url":"https://stock-news.laohu8.com/highlight/detail?id=2435151191","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435151191?lang=zh_cn&edition=full","pubTime":"2024-05-14 22:00","pubTimestamp":1715695235,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)05月14日在投资者关系平台上答复投资者关心的问题。投资者：请问截至2024年5月10日公司的股东数是多少？谢谢仁和药业董秘：谢谢您的关注！根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！投资者：请问公司有涉医美相关业务吗仁和药业董秘：谢谢您的关注！公司大健康业务板块涉及功效性化妆品业务，公司2023年度报告全文里有披露相关信息。谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051400034127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0188","BK0097"],"gpt_icon":0},{"id":"2434183955","title":"仁和药业：截止2024年4月30日，大约10万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2434183955","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434183955?lang=zh_cn&edition=full","pubTime":"2024-05-10 18:03","pubTimestamp":1715335409,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业05月10日在投资者关系平台上答复投资者关心的问题。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！投资者：董秘您好：请问截止到2024年4月30号，贵司最新股东人数是多少？截止2024年4月30日，大约10万户左右。在医药领域，合成生物的应用主要是药物中间体/原料药的合成以及人工改造生命体进行诊疗两大方面。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000035907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0188","BK0097"],"gpt_icon":0},{"id":"2431801036","title":"仁和药业（000650）4月29日主力资金净买入2178.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431801036","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431801036?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:22","pubTimestamp":1714440170,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月29日收盘，仁和药业报收于6.52元，下跌0.46%，换手率3.97%，成交量52.89万手，成交额3.44亿元。近5日资金流向一览见下表：仁和药业融资融券信息显示，融资方面，当日融资买入2726.65万元，融资偿还1440.82万元，融资净买入1285.83万元。仁和药业主营业务：生产、销售中西药、原料药及健康相关产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000018487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"gpt_icon":0},{"id":"2431882446","title":"图解仁和药业一季报：第一季度单季净利润同比减2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431882446","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431882446?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:39","pubTimestamp":1714383571,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业2024年一季报显示，公司主营收入12.38亿元，同比下降8.72%；归母净利润1.77亿元，同比下降2.74%；扣非净利润1.01亿元，同比下降42.28%；负债率11.89%，投资收益693.43万元，财务费用-677.05万元，毛利率36.66%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900022842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2431857886","title":"仁和药业最新公告：一季度归母净利润1.77亿元 同比下降2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431857886","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431857886?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:56","pubTimestamp":1714380970,"startTime":"0","endTime":"0","summary":"仁和药业发布2024年一季度报告，第一季度归母净利润1.77亿元，同比下降2.74%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900018807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"gpt_icon":0},{"id":"2431988642","title":"仁和药业：一季度净利润1.77亿元，同比下降2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431988642","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431988642?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:54","pubTimestamp":1714380840,"startTime":"0","endTime":"0","summary":"4月29日，仁和药业股份有限公司（仁和药业，000650）披露一季报，一季度实现营业收入12.38亿元，同比下降8.72%；净利润1.77亿元，同比下降2.74%；基本每股收益0.13元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-04-29/doc-inatnyix1244999.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-04-29/doc-inatnyix1244999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000650"],"gpt_icon":0},{"id":"2431007587","title":"仁和药业(000650.SZ)发布一季度业绩，净利润1.77亿元，下降2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431007587","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431007587?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:10","pubTimestamp":1714378212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仁和药业(000650.SZ)发布2024年第一季度报告，该公司营业收入为12.38亿元，同比减少8.72%。归属于上市公司股东的净利润为1.77亿元，同比减少2.74%。归属于上市公司股东的扣除非经常性损益的净利润为1.01亿元，同比减少42.28%。基本每股收益为0.1266元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000650"],"gpt_icon":0},{"id":"2430798294","title":"仁和药业(000650.SZ)发布2023年度业绩，净利润5.67亿元，下降1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430798294","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430798294?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:28","pubTimestamp":1714037323,"startTime":"0","endTime":"0","summary":"仁和药业(000650.SZ)发布2023年年度报告，报告期内，公司实现营业收入5...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/10.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/10.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["000650"],"gpt_icon":0},{"id":"2430475473","title":"仁和药业最新公告：拟使用合计不超30亿元进行投资理财","url":"https://stock-news.laohu8.com/highlight/detail?id=2430475473","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430475473?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:51","pubTimestamp":1714035066,"startTime":"0","endTime":"0","summary":"仁和药业公告，公司拟使用合计不超过人民币30亿元额度的自有经营性盈余资金进行投资理财，上述额度内的投资理财在公司董事会、股东会审议通过之日起12个月内有效并授权公司管理层负责具体实施相关事宜。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500033741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0239","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","stockEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.1161},{"period":"3month","weight":-0.0973},{"period":"6month","weight":-0.1041},{"period":"1year","weight":-0.0465},{"period":"ytd","weight":-0.1041}],"companyName":"仁和药业股份有限公司","boardCode":"AI0027","perCapita":"13585股","boardName":"医药制造业","registeredCapital":"139993万元","compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":-0.0432},{"period":"3month","weight":-0.0364},{"period":"6month","weight":0.0097},{"period":"1year","weight":-0.0823},{"period":"ytd","weight":-0.0058}],"survey":" 仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。公司是全国通过GMP认证生产线最多的企业之一。","serverTime":1720171309807,"listedPrice":6.26,"stockholders":"98000人(较上一季度减少2.00%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}